| 1. |
- Brinkmalm-Westman, Ann, 1966, et al.
(författare)
-
A Mass Spectrometer´s Building Blocks
- 2009
-
Ingår i: Mass Spectrometry: Instrumentation, Interpretation, and Applications. Eds. Rolf Ekman, Jerzy Silberring, Ann Westman-Brinkmalm, Agnieszka Kraj. - New York : Wiley. - 9780471713951 ; , s. 15-87
-
Bokkapitel (övrigt vetenskapligt/konstnärligt)abstract
- This chapter contains sections titled: * Ion Sources * Mass Analyzers * Detectors * References
|
|
| 2. |
- Brinkmalm-Westman, Ann, 1966, et al.
(författare)
-
Definitions and Explanations
- 2009
-
Ingår i: Mass Spectrometry: Instrumentation, Interpretation, and Applications. Eds. Rolf Ekman, Jerzy Silberring, Ann Westman-Brinkmalm, Agnieszka Kraj. - New York : Wiley. - 9780471713951 ; , s. 3-13
-
Bokkapitel (övrigt vetenskapligt/konstnärligt)abstract
|
|
| 3. |
- Brinkmalm-Westman, Ann, 1966, et al.
(författare)
-
Proteomics/peptidomics tools to find CSF biomarkers for neurodegenerative diseases.
- 2009
-
Ingår i: Frontiers in bioscience : a journal and virtual library. - : IMR Press. - 1093-4715. ; 14, s. 1793-806
-
Forskningsöversikt (refereegranskat)abstract
- Neurodegenerative diseases are characterized by premature neuronal loss in specific brain regions. During the past decades our knowledge on molecular mechanisms underlying neurodegeneration has increased immensely and resulted in promising drug candidates that might slow down or even stop the neuronal loss. These advances have put a strong focus on the development of diagnostic tools for early or pre-clinical detection of the disorders. In this review we discuss our experience in the field of neuroproteomics/peptidomics, with special focus on biomarker discovery studies that have been performed on CSF samples from well-defined patient and control populations.
|
|
| 4. |
- Brinkmalm-Westman, Ann, 1966, et al.
(författare)
-
Separation Methods
- 2009
-
Ingår i: Mass Spectrometry: Instrumentation, Interpretation, and Applications. Eds. Rolf Ekman, Jerzy Silberring, Ann Westman-Brinkmalm, Agnieszka Kraj. - New York : Wiley. - 9780471713951 ; , s. 105-115
-
Bokkapitel (övrigt vetenskapligt/konstnärligt)abstract
- This chapter contains sections titled: * Chromatography * Electric-Field Driven Separations * References
|
|
| 5. |
- Brinkmalm-Westman, Ann, 1966, et al.
(författare)
-
Tandem Mass Spectrometry
- 2009
-
Ingår i: Mass Spectrometry: Instrumentation, Interpretation, and Applications. Eds. Rolf Ekman, Jerzy Silberring, Ann Westman-Brinkmalm, Agnieszka Kraj. - New York : Wiley. - 9780471713951 ; , s. 89-103
-
Bokkapitel (övrigt vetenskapligt/konstnärligt)abstract
- This chapter contains sections titled: * Tandem MS Analyzer Combinations * Ion Activation Methods * References
|
|
| 6. |
- Portelius, Erik, 1977, et al.
(författare)
-
An Alzheimer's disease-specific beta-amyloid fragment signature in cerebrospinal fluid.
- 2006
-
Ingår i: Neuroscience letters. - : Elsevier BV. - 0304-3940. ; 409:3, s. 215-9
-
Tidskriftsartikel (refereegranskat)abstract
- Pathogenic events in Alzheimer's disease (AD) involve an imbalance between the production and clearance of the neurotoxic beta-amyloid peptide (Abeta), especially the 42 amino acid peptide Abeta1-42. While much is known about the production of Abeta1-42, many questions remain about how the peptide is degraded. To investigate the degradation pattern, we developed a method based on immunoprecipitation combined with matrix-assisted laser desorption/ionization time-of-flight mass spectrometry that determines the Abeta degradation fragment pattern in cerebrospinal fluid (CSF). We found in total 18 C-terminally and 2 N-terminally truncated Abeta peptides and preliminary data indicated that there were differences in the detected Abeta relative abundance pattern between AD and healthy controls. Here, we provide direct evidence that an Abeta fragment signature consisting of Abeta1-16, Abeta1-33, Abeta1-39, and Abeta1-42 in CSF distinguishes sporadic AD patients from non-demented controls with an overall accuracy of 86%.
|
|
| 7. |
|
|
| 8. |
- Portelius, Erik, 1977, et al.
(författare)
-
Characterization of tau in cerebrospinal fluid using mass spectrometry.
- 2008
-
Ingår i: Journal of proteome research. - : American Chemical Society (ACS). - 1535-3893 .- 1535-3907. ; 7:5, s. 2114-20
-
Tidskriftsartikel (refereegranskat)abstract
- The neurodegenerative disorder Alzheimer's disease (AD) is the most common cause of dementia in the elderly. The presence of neurofibrillary tangles, consisting of hyperphosphorylated tau protein, is one of the major neuropathologic characteristics of the disease, making this protein an attractive biomarker for AD and a possible target for therapy. Here, we describe an optimized immunoprecipitation mass spectrometry method that enables, for the first time, detailed characterization of tau in human cerebrospinal fluid. The identities of putative tau fragments were confirmed using nanoflow liquid chromatography and tandem mass spectrometry. Nineteen tryptic fragments of tau were detected, of which 16 are found in all tau isoforms while 3 represented unique tau isoforms. These results pave the way for clinical CSF studies on the tauopathies.
|
|
| 9. |
- Portelius, Erik, 1977, et al.
(författare)
-
Effects of gamma-Secretase Inhibition on the Amyloid beta Isoform Pattern in a Mouse Model of Alzheimer's Disease.
- 2009
-
Ingår i: Neuro-degenerative diseases. - : S. Karger AG. - 1660-2862 .- 1660-2854. ; 6:5-6
-
Tidskriftsartikel (refereegranskat)abstract
- Background:Accumulation of amyloid beta (Abeta) in the brain is believed to represent one of the earliest events in the Alzheimer disease process. Abeta is generated from amyloid precursor protein after sequential cleavage by beta- and gamma-secretase. Alternatively, alpha-secretase cleaves within the Abeta sequence, thus, precluding the formation of Abeta. A lot of research has focused on Abeta production, while less is known about the non-amyloidogenic pathway. We have previously shown that Abeta is present in human cerebrospinal fluid (CSF) as several shorter C-terminal truncated isoforms (e.g. Abeta1-15 and Abeta1-16), and that the levels of these shorter isoforms are elevated in media from cells that have been treated with gamma-secretase inhibitors. Objective:To explore the effect of N-[N-(3,5-difluorophenacetyl-L-alanyl)]-S-phenylglycine t-butyl ester (DAPT), a gamma-secretase-inhibitor, treatment on the Abeta isoform pattern in brain tissue and CSF from Tg2576 mice. Methods: Immunoprecipitation using the anti-Abeta antibodies 6E10 and 4G8 was combined with either matrix-assisted laser desorption/ionization time-of-flight mass spectrometry or nanoflow liquid chromatography and tandem mass spectrometry. Results: All fragments longer than and including Abeta1-17 displayed a tendency towards decreased levels upon gamma-secretase inhibition, whereas Abeta1-15 and Abeta1-16 indicated slightly elevated levels during treatment. Conclusion: These data suggest that Abeta1-15 and Abeta1-16 may be generated through a third metabolic pathway independent of gamma-secretase, and that these Abeta isoforms may serve as biomarkers for secretase inhibitor treatment.
|
|
| 10. |
- Portelius, Erik, 1977, et al.
(författare)
-
Identification of novel APP/Abeta isoforms in human cerebrospinal fluid.
- 2009
-
Ingår i: Neuro-degenerative diseases. - : S. Karger AG. - 1660-2862 .- 1660-2854. ; 6:3, s. 87-94
-
Tidskriftsartikel (refereegranskat)abstract
- BACKGROUND: Aggregation of beta-amyloid (Abeta) into oligomers and plaques is the central pathogenic mechanism in Alzheimer's disease (AD). Abeta is produced from the amyloid precursor protein (APP) by beta- and gamma-secretases, whereas, in the nonamyloidogenic pathway, alpha-secretase cleaves within the Abeta sequence, and thus precludes Abeta formation. A lot of research has focused on Abeta production and the neurotoxic 42-amino-acid form of Abeta (Abeta1-42), while less is known about the nonamyloidogenic pathway and how Abeta is degraded. OBJECTIVE: To study the Abeta metabolism in man by searching for novel Abeta peptides in cerebrospinal fluid (CSF). METHODS: Immunoprecipitation, using an anti-Abeta antibody, 6E10, was combined with either matrix-assisted laser desorption/ionization time-of-flight mass spectrometry or nanoflow liquid chromatography and tandem mass spectrometry. RESULTS: We identified 12 truncated APP/Abeta peptides in the CSF, all of which end at amino acid 15 in the Abeta sequence, i.e. 1 amino acid before the proposed alpha-secretase site. Of these 12 APP/Abeta peptides, 11 are novel peptides and start N-terminally of the beta-secretase site. The most abundant APP/Abeta peptide starts 25 amino acids before the beta-secretase site, APP/Abeta (-25 to 15), and had a concentration of approximately 80 pg/ml. The identity of all the APP/Abeta peptides was verified in a cohort of AD patients and controls. A first pilot study also showed that the intensity of several APP/Abeta peaks in CSF was higher in AD cases than in controls. CONCLUSION: These data suggest an enzymatic activity that cleaves the precursor protein in a specific manner that may reflect a novel metabolic pathway for APP and Abeta.
|
|
| 11. |
- Zetterberg, Henrik, 1973, et al.
(författare)
-
Clinical proteomics in neurodegenerative disorders.
- 2008
-
Ingår i: Acta neurologica Scandinavica. - : Hindawi Limited. - 1600-0404 .- 0001-6314. ; 118:1, s. 1-11
-
Forskningsöversikt (refereegranskat)abstract
- Neurodegenerative disorders are characterized by neuronal impairment that eventually leads to neuronal death. In spite of the brain's known capacity for regeneration, lost neurons are difficult to replace. Therefore, drugs aimed at inhibiting neurodegenerative processes are likely to be most effective if the treatment is initiated as early as possible. However, clinical manifestations in early disease stages are often numerous, subtle and difficult to diagnose. This is where biomarkers that specifically reflect onset of pathology, directly or indirectly, may have a profound impact on diagnosis making in the future. A triplet of biomarkers for Alzheimer's disease (AD), total and hyperphosphorylated tau and the 42 amino acid isoform of beta-amyloid, has already been established for early detection of AD before the onset of dementia. However, more biomarkers are needed both for AD and for other neurodegenerative disorders, such as Parkinson's disease, frontotemporal dementia and amyotrophic lateral sclerosis. This review provides an update on recent advances in clinical neuroproteomics, a biomarker discovery field that has expanded immensely during the last decade, and gives an overview of the most commonly used techniques and the major clinically relevant findings these techniques have lead to.
|
|
| 12. |
- Adden, Roland, et al.
(författare)
-
The Applicability of Enzymes in Cellulose Ether Analysis
- 2009
-
Ingår i: Macromolecular Symposia. - 1022-1360 .- 1521-3900. ; 280, s. 36-44
-
Konferensbidrag (refereegranskat)abstract
- Six methyl cellulose (MC) samples, one with a IDS Of 1.32 and five with a DS between 1.83 and 1.88, were degraded with five different enzymes or enzyme preparations containing endoglucanases. The main goal was to investigate whether enzymes could be used for determination of heterogeneity of the substituent distribution along the cellulose chain. To obtain information about the heterogeneity it was necessary to gather information on how the enzymes affect hydrolysis. Monomer composition and methyl distribution in the polymer chain were analyzed after total or partial random hydrolysis and appropriate derivatization by GC and MS, respectively, and used as reference data for the evaluation of the enzymatic hydrolysis. Size exclusion chromatography with multi angle light scattering and refractive index detection (SEC-MALLS/RI) was used to estimate molar mass distribution of the MCs before and after hydrolysis. Electrospray and matrix assisted laser desorption/ionization (ESI and MALDI) in combination with various MS analyzers were compared with respect to quantification of the degradation products directly and after perdeuteromethylation. Methyl group distribution in the oligomeric fractions and the average DS/DP were calculated from ESI mass spectra. With help of the reference analysis, patterns could be corrected for the unspecific contribution of end groups. By labelling and ESI-MSn, our knowledge about the tolerance of the enzyme's sub-sites with respect to the number of methyl groups could be improved. A novel standard addition method in combination with electrospray ionization ion trap mass spectrometry (ESI-IT MS) was used to determine the amount of formed oligomers.
|
|
| 13. |
- Nilsson, Jonas, 1970, et al.
(författare)
-
Enrichment of glycopeptides for glycan structure and attachment site identification.
- 2009
-
Ingår i: Nature methods. - : Springer Science and Business Media LLC. - 1548-7105 .- 1548-7091. ; 6:11, s. 809-11
-
Tidskriftsartikel (refereegranskat)abstract
- We present a method to enrich for glycoproteins from proteomic samples. Sialylated glycoproteins were selectively periodate-oxidized, captured on hydrazide beads, trypsinized and released by acid hydrolysis of sialic acid glycosidic bonds. Mass spectrometric fragment analysis allowed identification of glycan structures, and additional fragmentation of deglycosylated ions yielded peptide sequence information, which allowed glycan attachment site and protein identification. We identified 36 N-linked and 44 O-linked glycosylation sites on glycoproteins from human cerebrospinal fluid.
|
|
| 14. |
- Schagerlöf, Herje, et al.
(författare)
-
Substituent distribution and clouding behavior of hydroxypropyl methyl cellulose analyzed using enzymatic degradation
- 2006
-
Ingår i: Biomacromolecules. - : American Chemical Society (ACS). - 1526-4602 .- 1525-7797. ; 7:12, s. 3474-3481
-
Tidskriftsartikel (refereegranskat)abstract
- The distribution of substituents along the polymer backbone will have a strong influence on the properties of modified cellulose. Endoglucanases were used to degrade three different batches of hydroxypropyl methyl cellulose ( HPMC) derivatives with similar chemical properties. The phase separation of the HPMCs as a function of temperature, i.e., the clouding behavior, was analyzed prior to degradation. The total amount of unsubstituted glucose was determined using total acid hydrolysis followed by high-performance anion-exchange chromatography with pulsed amperometric detection (HPAEC-PAD). The products after enzymatic degradation were analyzed with size-exclusion chromatography with online multiangle light scattering and refractive index detection and also with reducing end determination. To further characterize the formed products, matrix-assisted laser desorption/ionization time-of-flight mass spectrometry was employed for analysis of short-chained oligosaccharides. The different endoglucanases showed varying degradation capability of HPMC derivatives, depending on structure of the active site. The investigated HPMCs had different susceptibility to degradation by the endoglucanases. The results showed a difference in substituent distribution between HPMC batches, which could explain the differing clouding behaviors. The batch with the lowest cloud point was shown to contain a higher number of non-degradable, highly substituted regions.
|
|
| 15. |
- Schagerlöf, Ulrika, et al.
(författare)
-
Endoglucanase sensitivity for substituents in methyl cellulose hydrolysis studied using MALDI-TOFMS for oligosaccharide analysis and structural analysis of enzyme active sites.
- 2007
-
Ingår i: Biomacromolecules. - : American Chemical Society (ACS). - 1525-7797 .- 1526-4602. ; 8:8, s. 2358-65
-
Tidskriftsartikel (refereegranskat)abstract
- The properties of modified cellulose polymers, such as methylcellulose, are significantly influenced by the distribution of substituents along the polymer backbone. This distribution is difficult to determine due to the lack of suitable analytical methods. One approach is to use cellulose-degrading enzymes to gain information from the capability of the enzymes to cleave the bonds between glucose units. Endoglucanases are cellulase enzymes that can break internal glycosidic linkages and degrade low substituted regions of modified cellulose where the substituents do not interfere with the enzyme active site. In this work methyl cellulose was degraded using five endoglucanases from glycosyl hydrolase families 5 and 7 from three different species. The products were analyzed with reducing end analysis, chromatography (SEC-MALS-RI), and MALDI-TOFMS. The results were correlated with available determined enzyme structures and using structural alignment for unknown enzyme structures. This was performed in order to elucidate the relationship between active site structures and sensitivity for substituents on derivatized cellulose. The evaluation of endoglucanase hydrolysis of methyl cellulose showed that differences in sensitivity could be related to differences in steric hindrance of substituents in the active site, which could explain differences within family 5 and 7 enzymes, as well as the generally higher substituent tolerance for family 5 enzymes. This information is important for use of endoglucanases as tools for characterization of substituent distribution. The results are also valuable since soluble cellulose derivatives are generally used as substrates during enzyme characterization and in endoglucanase activity assays.
|
|
